Literature DB >> 2828228

In vitro expansion of Epstein-Barr virus-specific HLA-restricted cytotoxic T cells direct from the blood of infectious mononucleosis patients.

G Strang1, A B Rickinson.   

Abstract

The cytotoxic T-cell response induced by primary Epstein-Barr virus (EBV) infection and detectable in the blood of infectious mononucleosis (IM) patients shows several unusual features when tested in in vitro assays. Lysis of EBV-transformed target lines occurs with no apparent HLA restriction, and the putative EBV specificity of the response has been seriously questioned. In the present work we show that the primary T-cell response in IM is polyclonal and indeed does contain a virus-specific HLA class I antigen-restricted component, which can be selectively expanded in vitro in the presence of appropriate stimulator cells and IL-2. This allows functional analysis of the virus-specific component of the response in the absence of co-resident reactivities. Studies on blood samples taken from individuals in the acute phase of IM and again post-convalescence suggest that functionally similar populations of HLA class I-restricted cytotoxic T cells are involved in the control of both the primary and persistent phase of EBV infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2828228      PMCID: PMC1454146     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  Studies on cytotoxicity generated in human mixed lymphocyte cultures. I. Time course and target spectrum of several distinct concomitant cytotoxic activities.

Authors:  J K Seeley; S H Golub
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

2.  EBV-related cytotoxicity of Fc receptor negative T lymphocytes separated from the blood of infectious mononucleosis patients.

Authors:  T Bakacs; E Svedmyr; E Klein
Journal:  Cancer Lett       Date:  1978-04       Impact factor: 8.679

3.  Fine specificity of a continuously growing killer cell clone specific for H-Y antigen.

Authors:  H von Boehmer; H Hengartner; M Nabholz; W Lernhardt; M H Schreier; W Haas
Journal:  Eur J Immunol       Date:  1979-08       Impact factor: 5.532

4.  Multiple HLA class I-dependent cytotoxicities constitute the "non-HLA-restricted" response in infectious mononucleosis.

Authors:  G Strang; A B Rickinson
Journal:  Eur J Immunol       Date:  1987-07       Impact factor: 5.532

5.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes.

Authors:  G Miller; T Shope; H Lisco; D Stitt; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

6.  Epstein Barr virus selective T cells in infectious mononucleosis are not restricted to HLA-A and B antigens.

Authors:  J Seeley; E Svedmyr; O Weiland; G Klein; E Moller; E Eriksson; K Andersson; L van der Waal
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

7.  Mitotic EBNA-positive lymphocytes in peripheral blood during infectious mononucleosis.

Authors:  J Robinson; D Smith; J Niederman
Journal:  Nature       Date:  1980-09-25       Impact factor: 49.962

8.  Cell-mediated immunity to Epstein-Barr-virus-transformed lymphoblastoid cells in acute infectious mononucleosis.

Authors:  I Royston; J L Sullivan; P O Periman; E Perlin
Journal:  N Engl J Med       Date:  1975-12-04       Impact factor: 91.245

9.  The cellular basis for viral-induced immunodeficiency: analysis by monoclonal antibodies.

Authors:  E L Reinherz; C O'Brien; P Rosenthal; S F Schlossman
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

10.  Increased numbers of cells with suppressor T cell phenotype in the peripheral blood of patients with infectious mononucleosis.

Authors:  D H Crawford; P Brickell; N Tidman; I McConnell; A V Hoffbrand; G Janossy
Journal:  Clin Exp Immunol       Date:  1981-02       Impact factor: 4.330

View more
  8 in total

1.  Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.

Authors:  S Pepperl; G Benninger-Döring; S Modrow; H Wolf; W Jilg
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

2.  Emergence of non-major-histocompatibility-complex-restricted lytic CD8+ cells in the blood of nasopharyngeal carcinoma patients.

Authors:  M Lakhdar; H Thameur; M Maalej; F Ben Ayed; A Ladgham
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

Review 3.  T-cell memory: lessons from Epstein-Barr virus infection in man.

Authors:  A B Rickinson; M F Callan; N E Annels
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-03-29       Impact factor: 6.237

4.  Massive expansion of antigen-specific CD8+ T cells during an acute virus infection.

Authors:  E A Butz; M J Bevan
Journal:  Immunity       Date:  1998-02       Impact factor: 31.745

5.  Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.

Authors:  Ryan Incrocci; Samira Hussain; Amanda Stone; Kathryn Bieging; Lauren A C Alt; Michael J Fay; Michelle Swanson-Mungerson
Journal:  Cell Immunol       Date:  2015-08-04       Impact factor: 4.868

6.  Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory.

Authors:  N M Steven; A M Leese; N E Annels; S P Lee; A B Rickinson
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

7.  Pathogenesis of an infectious mononucleosis-like disease induced by a murine gamma-herpesvirus: role for a viral superantigen?

Authors:  R A Tripp; A M Hamilton-Easton; R D Cardin; P Nguyen; F G Behm; D L Woodland; P C Doherty; M A Blackman
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

8.  Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis.

Authors:  S L Silins; S M Cross; S L Elliott; S J Pye; S R Burrows; J M Burrows; D J Moss; V P Argaet; I S Misko
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.